Methods of detecting disorders of the central nervous system by detecting autoantibodies which specifically bind ionotropic glutamate receptors
US5529898A · kind A · utility
3Cited by
2References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 19, 1993 |
| Grant date | Jun 25, 1996 |
| Priority date | — |
| Expiry date | Aug 19, 2013 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/811
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method of screening a subject for a central nervous system disorder caused by autoimmune disease (e.g., an inflammatory seizure disorder) comprises a sample from the subject and then detecting the presence or absence of anti-glutamate receptor autoantibodies (e.g., anti-GluR3 glutamate receptor autoantibodies) in the biological sample. The presence of such autoantibodies indicates the subject is afflicted with a central nervous system disorder caused by autoimmune disease. Methods of treating such disease by reducing the number of autoantibodies available to bind to glutamate receptors in the subject are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.